Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice

Experimental Gerontology

Volumn 45, Issue 3, 2010, Pages 202-207

  D'Amico, Michele ^a   Di Filippo, Clara ^a   Marfella, Raffaele ^a   Abbatecola, Angela Maria ^a   Ferraraccio, Franca ^a   Rossi, Francesco ^a   Paolisso, Giuseppe ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Amyloid; Alzheimer's; Dipeptidyl peptidase 4; Interleukin 1 ; Mice; Sitagliptin

Indexed keywords

3 NITROTYROSINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 1BETA; SITAGLIPTIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME INHIBITION; HIPPOCAMPUS; INFLAMMATION; MEMORY DISORDER; MENTAL PERFORMANCE; MOUSE; NITROSATIVE STRESS; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; PYRAZINES; TRIAZOLES;

MUS; MUS MUSCULUS;

EID: 76749116176     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2009.12.004     Document Type: Article

References (34)

1. Atkins C.M., Selcher J.C., Petraitis J.J., Trzaskos J.M., and Sweatt J.D. The MAPK cascade is required for mammalian associative learning. Nat. Neurosci. 1 (1998) 602-609
2. Beconi M.G., Reed J.R., Teffera Y., Xia Y.Q., Kochansky C.J., Liu D.Q., Xu S., Elmore C.S., Ciccotto S., Hora D.F., Stearns R.A., and Vincent S.H. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab. Dispos. 35 (2007) 525-532
3. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 68 (2006) 387-403
4. Brown J.B., Nichols G.A., and Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 27 (2004) 1535-1540
5. Bryan K.J., Zhu X., Harris P.L., Perry G., Castellani R.J., Smith M.A., and Casadesus G. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease. Mol. Neurodegener. 3 (2008) 13-18
6. Cani P.D., Knauf C., Iglesias M.A., Drucker D.J., Delzenne N.M., and Burcelin R. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 55 (2006) 1484-1490
7. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003) 2929-2940
8. Drucker D.J. The biology of incretin hormones. Cell. Metab. 3 (2006) 153-165
9. Gallwitz B. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vasc. Health Risk Manag. 3 (2007) 203-210
10. Hansen L., Deacon C.F., Orskov C., and Holst J.J. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140 (1999) 5356-5363
11. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., and Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13 (2004) 159-170
12. Jiang Q., Heneka M., and Landreth G.E. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 22 (2008) 1-14
13. Kim J.J., DeCola J.P., Landeria-Fernandez J., and Fanselow M.S. N-methyl-d-aspartate receptor antagonist APV blocks acquisition but not expression of fear conditioning. Behav. Neurosci. 105 (1991) 126-133
14. Knauf C., Cani P.D., Perrin C., Iglesias M.A., Maury J., Bernard E., Benhamed F., Gremeaux T., Drucker D.J., Kahn C.R., Girard J., Tanti J., Delzenne N.M., Postic C., and Burcelin R. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J. Clin. Invest. 112 (2005) 3554-3563
15. Knecht L.A., Gauthier S.M., Castro J.C., Schmidt R.E., Whitaker M.D., Zimmerman R.S., Mishark K.J., and CooK C.B. Diabetes care in the hospital: is there clinical inertia?. J. Hosp. Med. 1 (2006) 151-160
16. Knudsen L.B., and Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318 (1996) 429-435
17. Kubis A.M., and Janusz M. Alzheimer's disease: new prospects in therapy and applied experimental models. Postepy Hig. Med. Dosw. 62 (2008) 372-392
18. Lamont B.J., and Drucker D.J. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 57 (2008) 190-198
19. Larsen J., Hylleberg B., Ng K., and Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 24 (2001) 1416-1421
20. Larson E.B., Shadlen M.F., Wang L., McCormick W.C., Bowen J.D., Teri L., and Kukul W.A. Survival after initial diagnosis of Alzheimer disease. Ann. Intern. Med. 140 (2004) 501-509
21. Lesnè S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
22. Li L. Is glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?. Neurosci. Bull. 23 (2007) 8-65
23. Logue S.F., Paylor R., and Wehner J.M. Hippocampal lesions cause learning deficits in inbred mice in the Morris water maze and conditioned-fear task. Behav. Neurosci. 111 (1997) 104-113
24. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J., and Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 97 (2000) 6874-6879
25. Meier J.J., and Nauck M.A. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best Pract. Res. Clin. Endocrinol. Metab. 18 (2004) 587-606
26. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214 (1993) 829-835
27. Mohajeri M.H., Saini K.D., and Nitsch R.M. Transgenic BACE expression in mouse neurons accelerates amyloid plaque pathology. J. Neural Transm. 111 (2004) 413-425
28. Onozuka H., Nakajima A., Matsuzaki K., Shin R.W., Ogino K., Saigusa D., Tetsu N., Yokosuka A., Sashida Y., Mimaki Y., Yamakuni T., and Ohizumi Y. Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 326 (2008) 739-744
29. Perry T., and Greig N.H. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J. Alzheimers Dis. 4 (2002) 487-496
30. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., and Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 72 (2003) 603-612
31. Raun K., von Voss P., Gotfredsen C.F., Golozoubova V., Rolin B., and Knudsen L.B. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56 (2007) 8-15
32. Reitz C., Brickman A.M., Luchsinger J.A., Wu W.E., Small S.A., and Tang M.X. Frequency of subclinical heart disease in elderly persons with dementia. Am. J. Geriatr. Cardiol. 16 (2007) 183-188
33. Singer R.B. Mortality derived from 5-year survival in patients with Alzheimer disease. J. Insur. Med. 37 (2005) 264-271
34. Vilsboll T., Krarup T., Sonne J., Madsbad S., Vølund A., Juul A.G., and Holst J.J. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 88 (2003) 2706-2713